Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

India Considers Grants To Private Firms That Find Disease Cures

This article was originally published in PharmAsia News

Executive Summary

India is considering creation of an $11 million grant program for drug makers in private industry that develop drugs for major tropical diseases such as tuberculosis. The grant system for private sector companies would be in addition to grants for public-funded research industries and soft loans already allowed to private companies. The Cabinet Committee on Economic Affairs has received a proposal from the Department of Science and Technology, which runs the grant program for public institutions. Targeted diseases include malaria and leprosy in addition to TB. (Click here for more

Table

View full table

Tags:
Latest Headlines

Amgen Planning Pivotal Obesity Program For MariTide

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

See All
UsernamePublicRestriction

Register

SC067866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By